Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial

The Lancet · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles